Zaviralci tirozin kinaze BCR-ABL (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zaviralci tirozin kinaze BCR-ABL" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

2^nd place

5^th place

4^th place

8^th place

low place

34^th place

6^th place

9^th place

archive.org

An, X.; Tiwari, A.; Sun, Y.; Ding, P.; Ashby Jr, C.; Chen, Z. (2010). »BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review«. Leukemia Research. 34 (10): 1255–1268. doi:10.1016/j.leukres.2010.04.016. PMID 20537386.
Eck, M.; Manley, P. (2009). »The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl«. Current Opinion in Cell Biology. 21 (2): 288–295. doi:10.1016/j.ceb.2009.01.014. PMID 19217274.
Mandal, S.; Moudgil, M.; Mandal, S. (2009). »Rational drug design«. European Journal of Pharmacology. 625 (1–3): 90–100. doi:10.1016/j.ejphar.2009.06.065. PMID 19835861.
Asaki, T.; Sugiyama, Y.; Hamamoto, T.; Higashioka, M.; Umehara, M.; Naito, H.; Niwa, T. (2006). »Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors«. Bioorganic & Medicinal Chemistry Letters. 16 (5): 1421–1425. doi:10.1016/j.bmcl.2005.11.042. PMID 16332440.
Mahon (1. avgust 2000). »Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance«. Blood. 96 (3): 1070–9. doi:10.1182/blood.V96.3.1070. PMID 10910924.
Rossari, F., Minutolo, F. & Orciuolo, E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol 11, 84 (2018). https://doi.org/10.1186/s13045-018-0624-2.

An, X.; Tiwari, A.; Sun, Y.; Ding, P.; Ashby Jr, C.; Chen, Z. (2010). »BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review«. Leukemia Research. 34 (10): 1255–1268. doi:10.1016/j.leukres.2010.04.016. PMID 20537386.
Eck, M.; Manley, P. (2009). »The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl«. Current Opinion in Cell Biology. 21 (2): 288–295. doi:10.1016/j.ceb.2009.01.014. PMID 19217274.
Mandal, S.; Moudgil, M.; Mandal, S. (2009). »Rational drug design«. European Journal of Pharmacology. 625 (1–3): 90–100. doi:10.1016/j.ejphar.2009.06.065. PMID 19835861.
Asaki, T.; Sugiyama, Y.; Hamamoto, T.; Higashioka, M.; Umehara, M.; Naito, H.; Niwa, T. (2006). »Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors«. Bioorganic & Medicinal Chemistry Letters. 16 (5): 1421–1425. doi:10.1016/j.bmcl.2005.11.042. PMID 16332440.
Mahon (1. avgust 2000). »Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance«. Blood. 96 (3): 1070–9. doi:10.1182/blood.V96.3.1070. PMID 10910924.